RDGL · XBRL financial data

Vivos financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RDGL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	—	5	—
Revenue from contracts with customers	7	15	36	20	28	68
Cost of goods and services sold	6	12	29	26	31	128
Gross profit	1	3	8	(6)	(3)	(60)
Research and development	85	287	344	733	325	352
General and administrative	109	112	151	166	242	297
Total operating expenses	674	2,505	2,525	2,787	2,601	3,105
Operating income (loss)	(673)	(2,502)	(2,518)	(2,793)	(2,604)	(3,165)
Interest expense	287	25	—	—	—	—
Income tax expense (benefit)	0	0	—	—	—	—
Net income (loss)	(957)	(2,528)	(2,470)	(2,895)	(2,910)	(3,066)
Earnings per share, basic USD per share	—	(0.01)	(0.01)	(0.01)	(0.01)	(0.01)
Earnings per share, diluted USD per share	—	—	(0.01)	(0.01)	(0.01)	(0.01)
Weighted average shares, basic thousands of shares	222,804	325,852	351,426	368,805	409,674	452,722
Weighted average shares, diluted thousands of shares	—	—	351,426	368,805	409,674	452,722

Fiscal years (RDGL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	904	1,606	1,706	1,592	2,213	1,559
Accounts receivable	—	—	11	7	10	22
Inventory	—	—	—	—	—	57
Total current assets	938	1,634	1,743	1,610	2,233	1,651
Property and equipment, net	—	—	—	—	—	103
Right-of-use asset	—	—	—	—	—	111
Total assets	938	1,634	1,743	1,610	2,233	1,868
Total current liabilities	906	167	82	245	86	118
Lease liability, non-current	—	—	—	—	—	89
Total liabilities	906	167	82	245	86	207
Accumulated deficit	(74,558)	(77,086)	(79,556)	(82,451)	(85,361)	(88,427)
Total stockholders' equity	32	1,467	1,661	1,365	2,147	1,661
Total liabilities and equity	938	1,634	1,743	1,610	2,233	1,868
Common shares outstanding (cover page) thousands of shares	297,346	343,531	362,542	389,894	453,374	482,688

Fiscal years (RDGL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(957)	(2,528)	(2,470)	(2,895)	(2,910)	(3,066)
Stock-based compensation	2	1,614	—	—	—	—
Net cash from operating activities	(876)	(964)	(1,120)	(1,293)	(1,684)	(2,058)
Purchases of property and equipment	—	—	—	—	—	103
Net cash from investing activities	—	—	—	—	—	(103)
Proceeds from issuing common stock	—	—	—	—	2,266	—
Proceeds from issuing equity	—	1,811	1,220	1,179	—	—
Net cash from financing activities	1,759	1,666	1,220	1,179	2,304	1,507
Net change in cash	883	702	100	(114)	620	(654)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Vivos	2,336	36	(740)*	494.2M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Fractyl Health	47,140	not reported	(15,901)*	159.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Monogram Technologies	12,834	not reported	(2,297)*	40.6M	5.6 quarters	Q2 FY25 10-QJun 30, 2025
Milestone Scientific	2,067	not reported	(585)*	88.7M	3.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.